$BPTH
BIO-PATH HOLDINGS, INC.

2015 Q3 Form 10-Q Financial Statement

#000114420415047730 Filed on August 10, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $520.0K $570.0K $750.0K
YoY Change -26.76% -24.0% 212.5%
% of Gross Profit
Research & Development $992.0K $564.0K $517.0K
YoY Change 133.68% 9.08% 231.36%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K $40.00K
YoY Change 25.0% 25.0% 0.0%
% of Gross Profit
Operating Expenses $1.512M $1.131M $1.275M
YoY Change 31.01% -11.28% 197.4%
Operating Profit -$1.512M -$1.131M -$1.275M
YoY Change 31.01% -11.28% 197.4%
Interest Expense $0.00 $10.00K $10.00K
YoY Change -100.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $4.000K $5.000K $6.024K
YoY Change -29.81% -17.0% 329.67%
Pretax Income -$1.510M -$1.130M -$1.270M
YoY Change 31.3% -11.02% 195.35%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.508M -$1.126M -$1.269M
YoY Change 31.31% -11.25% 196.97%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.356M -$2.511M -$2.822M
COMMON SHARES
Basic Shares Outstanding 89.76M shares 89.76M shares 89.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.850M $11.08M $15.72M
YoY Change -32.72% -29.52% 714.51%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $200.8K $950.0K $171.6K
YoY Change -30.77% 453.73% 269.66%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $10.46M $12.03M $16.03M
YoY Change -29.94% -24.97% 611.73%
LONG-TERM ASSETS
Property, Plant & Equipment $82.27K $92.56K
YoY Change
Goodwill
YoY Change
Intangibles $1.130M $1.171M $1.331M
YoY Change -12.44% -12.07% -10.77%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.213M $1.263M $1.331M
YoY Change 1733.98% -5.15% -10.77%
TOTAL ASSETS
Total Short-Term Assets $10.46M $12.03M $16.03M
Total Long-Term Assets $1.213M $1.263M $1.331M
Total Assets $11.67M $13.29M $17.37M
YoY Change -28.32% -23.45% 363.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $127.1K $385.1K $78.92K
YoY Change 43.62% 387.96% -52.43%
Accrued Expenses $354.1K $310.0K $149.3K
YoY Change 86.37% 107.58% 2952.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $481.2K $690.0K $333.5K
YoY Change 71.87% 106.88% 24.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $481.2K $690.0K $333.5K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $481.2K $690.0K $333.5K
YoY Change 71.87% 106.88% 24.51%
SHAREHOLDERS EQUITY
Retained Earnings -$23.93M -$22.42M
YoY Change
Common Stock $89.76K $89.24K
YoY Change 18.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.19M $12.60M $17.03M
YoY Change
Total Liabilities & Shareholders Equity $11.67M $13.29M $17.37M
YoY Change -28.32% -23.47% 363.74%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$1.508M -$1.126M -$1.269M
YoY Change 31.31% -11.25% 196.97%
Depreciation, Depletion And Amortization $50.00K $50.00K $40.00K
YoY Change 25.0% 25.0% 0.0%
Cash From Operating Activities -$1.220M -$1.370M -$1.100M
YoY Change 19.61% 24.55% 92.98%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.220M -1.370M -1.100M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -1.220M -1.370M -1.100M
YoY Change 11.93% 24.55% -167.07%
FREE CASH FLOW
Cash From Operating Activities -$1.220M -$1.370M -$1.100M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$1.220M -$1.100M
YoY Change 28.42% 92.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89762872 shares
dei Trading Symbol
TradingSymbol
BPTH
CY2015Q2 us-gaap Cash
Cash
11079999 USD
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30852 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10284 USD
CY2015Q2 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
2500374 USD
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
385073 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
41026 USD
CY2015Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0 USD
CY2014Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
100450 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19917245 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2014Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
2500374 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1329793 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1249481 USD
us-gaap Net Income Loss
NetIncomeLoss
-2500176 USD
us-gaap Net Income Loss
NetIncomeLoss
-1773654 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
517040 USD
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22417421 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
80312 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
80312 USD
us-gaap Depreciation
Depreciation
20568 USD
us-gaap Depreciation
Depreciation
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
541177 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
89981 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
153121 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
107446 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
130233 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
38621 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2778799 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1643077 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13812373 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13812373 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-2778799 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
12169296 USD
CY2013Q4 us-gaap Cash
Cash
3551832 USD
CY2014Q2 us-gaap Cash
Cash
15721128 USD
us-gaap Share Based Compensation
ShareBasedCompensation
184562 USD
CY2015Q2 us-gaap Revenues
Revenues
0 USD
CY2014Q2 us-gaap Revenues
Revenues
0 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
564350 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
566587 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
754548 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
1130937 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
1274801 USD
CY2015Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
CY2014Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
42 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6024 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-1125536 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-1268777 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89762872 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89237872 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
624681 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1135400 USD
us-gaap Share Based Compensation
ShareBasedCompensation
209071 USD
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89762872 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89762872 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89762872 shares
CY2014Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2509831 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1785012 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
9655 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
11639 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
281 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9655 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11358 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89762872 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89237872 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.39 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.78 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
bpth Supply Agreement Consideration To Be Paid In Stages
SupplyAgreementConsiderationToBePaidInStages
200000 USD
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2014Q4 bpth Accounts Payable And Accrued Liabilities Related Party Current
AccountsPayableAndAccruedLiabilitiesRelatedPartyCurrent
67050 USD
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
342000 USD
bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
190000 USD
bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
370000 USD
CY2013Q4 bpth Authorised Capital To Be Raised
AuthorisedCapitalToBeRaised
100000000 USD
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
13800000 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000 shares
CY2015Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
385073 USD
CY2014Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
41026 USD
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89762872 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q1 bpth Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
15000000 USD
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
93275 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
184562 USD
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
122793 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
209071 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1700000 USD
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123410 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123410 USD
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92558 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
113126 USD
CY2015Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1170581 USD
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1250893 USD
CY2015Q2 us-gaap Assets
Assets
13292596 USD
CY2014Q4 us-gaap Assets
Assets
15477978 USD
CY2014Q1 bpth Warrants Exercisable Term
WarrantsExercisableTerm
P5Y

Files In Submission

Name View Source Status
0001144204-15-047730-index-headers.html Edgar Link pending
0001144204-15-047730-index.html Edgar Link pending
0001144204-15-047730.txt Edgar Link pending
0001144204-15-047730-xbrl.zip Edgar Link pending
bpth-20150630.xml Edgar Link completed
bpth-20150630.xsd Edgar Link pending
bpth-20150630_cal.xml Edgar Link unprocessable
bpth-20150630_def.xml Edgar Link unprocessable
bpth-20150630_lab.xml Edgar Link unprocessable
bpth-20150630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v416978_10q.htm Edgar Link pending
v416978_ex31.htm Edgar Link pending
v416978_ex32.htm Edgar Link pending